Liquid biopsies analyze circulating tumor DNA and other biomarkers in blood to detect cancer noninvasively. Foundational work by Bert Vogelstein and Nickolas Papadopoulos at Johns Hopkins University demonstrated that tumor-specific mutations can appear in circulating cell-free DNA, establishing the biological plausibility for blood-based cancer detection. Clinical implementation requires translating that proof of principle into tests with reliable sensitivity, specificity, and actionable follow-up pathways.
How they perform in early detection
In practice, liquid biopsies are more effective at detecting advanced cancers than very early-stage disease. Many clinical studies and development programs for multicancer early detection tests show high specificity but variable sensitivity that generally increases with tumor stage. Biological factors such as tumor DNA shedding, tumor size, and vascular access strongly influence detectability. Technical parameters—sequencing depth, error suppression, and targeted panels versus genome-wide approaches—also determine performance. Because population prevalence of individual cancers is low, even tests with strong specificity can yield limited positive predictive value when deployed for broad screening, necessitating careful validation and diagnostic pathways.
Causes and consequences for clinical practice
Causes of current limitations include low tumor burden in early disease, heterogeneous mutation profiles across cancers, and noncancer sources of cell-free DNA. Consequences for patients and health systems range from earlier diagnosis when detection is successful to potential harms when false positives lead to invasive diagnostic procedures. Health systems face trade-offs: integrating liquid biopsy screening could improve outcomes for some cancer types but also create resource and access pressures. Cultural and territorial nuances are important; adoption and benefit will vary by healthcare infrastructure, screening norms, and population risk. In high-income settings with established diagnostic capacity, liquid biopsy might supplement current screening programs, whereas in low-resource regions limited access to follow-up diagnostics could reduce net benefit and exacerbate inequities.
Regulatory and guideline bodies emphasize the need for large prospective trials that measure clinical endpoints rather than analytic performance alone. Ongoing research aims to improve early-stage sensitivity, refine risk-based deployment, and define appropriate care pathways so that liquid biopsies realize potential benefits without unintended harms. Practical effectiveness in routine clinical practice depends on test performance, clinical validation, and equitable implementation.